Skip to content

The impact of Brexit on life sciences

Author
Rudoni Alexandre
Alexandre Rudoni

Partner

Paris

View profile →

14 March 2016

2015 marked the 50th anniversary of pharmaceutical legislation in the EU, which all started with Council Directive 65/65 in 1965 in the wake of the Thalidomide disaster in the early 1960s.

2015 marked the 50th anniversary of pharmaceutical legislation in the EU, which all started with Council Directive 65/65 in 1965 in the wake of the Thalidomide disaster in the early 1960s. Since the introduction of Council Directive 65/65, a sophisticated, integrated framework of EU law has evolved for medicinal and other products for human use that safeguards public health as well as promoting the development of the life sciences industry and trade in medicinal products. In light of the depth and breadth of EU regulation governing life sciences firms, a Brexit could be a catalyst for a wide range of unintended consequences. We consider below some of the key issues that life sciences firms globally may need to grapple with in the areas of regulation, intellectual property and commercial transactions.